Fact Sheet Q1 2026 | Sartorius Group

Company profile

Sartorius is a leading international partner of the biopharma industry. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. Founded in 1870, Sartorius currently employs around 14,000 people in more than 35 countries. Its operational business is subdivided into two divisions: Bioprocess Solutions and Lab Products & Services.

Investment Highlights

1. Focus on the high-growth biopharma market
2. Broad and differentiating product offering
3. Strong global presence
4. High share of recurring business; significant market entry barriers
5. Proven track record with alliances and acquisitions;
6. High continuity with respect to customer base, employees and management

Key Figures

in millions of € unless otherwise specified

	Q1 2026	Δ in %	Q1 2025	FY 2025	FY 2024	FY 2023
Sales revenue (% Δ in const. fx)	899.1	+7.5	883.0	3,538.1	3,380.7	3,395.7
Underlying EBITDA[1]	267.3	+1.6	263.0	1,051.6	945.3	962.7
Underlying EBITDA margin[1] in %	29.7	-0.1 pp	29.8	29.7	28.0	28.3
Underlying net profit[2]	83.2	-1.9	84.8	330.7	279.9	338.5
Underlying EPS per ordinary share[2] in €	1.20	-2.0	1.22	4.78	4.05	4.94
Underlying EPS per preference share[2] in €	1.21	-1.9	1.23	4.79	4.06	4.95
Equity ratio[3] in %	39.4	+1.4 pp	38.0	39.8	38.6	28.3
Net debt to underlying EBITDA[1,4]	3.53	-	3.89	3.55	3.96	5.05

1 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
2 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.
3 Equity in relation to the balance sheet total
4 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period

Sales Revenue by Division 2025



Sales Revenue by Region 2025



EMEA = Europe | Middle East | Africa

Underlying Earnings per Share[1] in €



1 After non-controlling interest, adjusted for extraordinary items as well as amortization, and based on a normalized financial result and the normalized tax rate

2026 Guidance

	Sales Revenue Growth[1]	EBITDA-Margin[2]
Sartorius Group	~5% to ~9%	Slightly above 30%
Bioprocess Solutions	~6% to ~10%	Slightly above 32%
Lab Products & Services	~2% to ~6%	Slightly below 21%
Capex Ratio	At ~PY level (~12.5%)	
Net debt to underlying EBITDA[3]	Slightly above 3	

1 in constant currencies
2 underlying = excluding extraordinary items
3 excluding potential capital measures and/or acquisitions

Division Strategy

Bioprocess Solutions

- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers' production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and cell cultivation
- One of the widest portfolios in the industry; clear focus on single-use technologies such as filters, bags and cell culture media
- Continuous expansion through complementary acquisitions and targeted alliances

Lab Products & Services

- Premium provider of laboratory instruments, consumables and services for sample preparation and bioanalytic
- Leading international positions in laboratory balances, pipettes and lab consumables
- Outstanding brand reputation, strong product range and global services as the basis for further expansion of market share
- Extension of portfolio with complementary laboratory products through acquisitions and alliances

Facts about Preference Shares

Ticker symbol: SRT3
Ticker symbol Bloomberg: SRT3 GY
Ticker symbol Reuters: SATG_pe.DE
WKN | ISIN: 716 563 | DE0007165631

Facts about Ordinary Shares

Ticker symbol: SRT
Ticker symbol Bloomberg: SRT GY
Ticker symbol Reuters: SATG
WKN | ISIN: 716 560 | DE0007165607

Sartorius Shares in Comparison (indexed)

April 1, 2025, to March 31, 2026



Shareholder Structure: Ordinary Shares

March 31, 2026



Shareholder Structure: Preference Shares

March 31, 2026



The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. The legal disclosure requirements refer only to ordinary shares and not to non-voting preference shares.

Financial calendar

July 23, 2026
Publication Half-year Report

October 22, 2026
Publication 9M Results

Disclaimer

This fact sheet contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbour risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.

Petra Müller
Head of Investor Relations
Tel.: +49.551.308.6035
Email: petra.mueller2@sartorius.com